References
- 1. Aoki T, Tsuchida M, Watanabe T, Hashimoto T, Koike T, Hirono T, Hayashi J. Surgical strategy for clinical stage I non-small cell lung cancer in octogenarians. // Eur J Cardiothorac Surg, 2003; 23(4):446-450.10.1016/S1010-7940(03)00014-9
- 2. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. // Biomark Med, 2013; 7(1):49-58.10.2217/bmm.12.111
- 3. Chida M, Minowa M, Karube Y, Eba S, Okada Y, Miyoshi S, Kondo T. Worsened long-term outcomes and postoperative complications in octogenarians with lung cancer following mediastinal lymphnode dissection. // Interact CardioVasc Thorac Surg, 2009; 8(1):89-92.10.1510/icvts.2008.193383
- 4. Das-Neves-Pereira JC, Bagan P, Coimbra-Israel AP, Grimaillof-Junior A, Cesar-Lopez G, Milanez-de- Campos JR, Riquet MR, Biscegli-Jatene F. Fasttrack rehabilitation for lung cancer lobectomy: a five-year experience. // Eur J Cardiothorac Surg, 2009; 36(2):383-392.10.1016/j.ejcts.2009.02.020
- 5. Gao WM, Kuick R, Orchekowski RP, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. // BMC Cancer, 2005; 5:110.10.1186/1471-2407-5-110
- 6. Giovannetti R, Alifano M, Stefani A, Legras A, Grigoroiu M, Collet JY, Magdelenat P, Regnard JF. Surgical treatment of bronchiectasis: early and long-term results. // Interact CardioVasc Thorac Surg, 2008; 7(4):609-612.10.1510/icvts.2007.163972
- 7. Ferguson MK, Celauro AD, Vigneswaran WT. Validation of a modified scoring system for cardiovascular risk associated with major lung resection. // Eur J Cardiothorac Surg, 2012; 41(3):598-602.10.1093/ejcts/ezr081
- 8. Ferguson MK and Durkin AE. A comparison of three scoring systems for predicting complications after major lung resection. // Eur J Cardiothorac Surg, 2003; 23(1):35-42.10.1016/S1010-7940(02)00675-9
- 9. Khan N, Cromer CJ, Campa M, et al. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. // Cancer, 2004; 101:379-384.10.1002/cncr.2037715241837
- 10. Kojima F, Yamamoto K, Matsuoka K, Ueda M, Hamada H, Imanishi N, Miyamoto Y. Factors affecting survival after lobectomy with pulmonary artery resection for primary lung cancer. // Eur J Cardiothorac Surg, 2011; 40(1):13-20.10.1016/j.ejcts.2011.02.02621435895
- 11. Kouritas VK, Zissis C and Bellenis I. Variation of the postoperative fluid drainage according to the type of lobectomy. // Interact CardioVasc Thorac Surg, 2013; 16(4):437-440.10.1093/icvts/ivs529
- 12. López E, Cho WC. Phosphoproteomics and lung cancer research. // Int J Mol Sci, 2012; 13(10):12287-314.10.3390/ijms131012287
- 13. Matsuoka H, Okada M, Sakamoto T, Tsubota N. Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of age. // Eur J Cardiothorac Surg, 2005; 28(3):380-383.10.1016/j.ejcts.2005.06.010
- 14. Paesmans M. Prognostic and predictive factors for lung cancer. Review. // Eur Respir J Breathe, 2012; 9:113 - 122.
- 15. Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Romero-Romero B, Mediano MD, López-Campos JL, García-Carbonero R, Sanchez-Gastaldo A, Carnero A, Paz-Ares L. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. // Int J Mol Sci, 2013; 14(2):3440-55.10.3390/ijms14023440
- 16. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. // J Clin Oncol, 2007; 25:5578-5583.10.1200/JCO.2007.13.5392
- 17. Sakuragi T, Sakao Y, Furukawa K, Rikitake K, Ohtsubo S, Okazaki Y, Natsuaki M, Itoh T. Successful management of acute pulmonary embolism after surgery for lung cancer. // Eur J Cardiothorac Surg, 2003; 24(4):580-587.10.1016/S1010-7940(03)00392-0
- 18. Szczesny TJ, Slotwinski R, Stankiewicz A, Szczygiel B, Zaleska M, Kopacz M. Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery. // Eur J Cardiothorac Surg, 2007; 31(4):719-724.10.1016/j.ejcts.2007.01.02717317198
- 19. Taenzer A, Alix-Panabières C, Wikman H, Pantel K. Circulating tumor-d erived biomarkers in lung cancer. // J Thorac Dis, 2012; 4(5):448-9.
- 20. Wang Y, Hu Y, Wang D, Yu K, Wang L, Zou Y, Zhao C, Zhang X, Wang P, Ying K. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. // Cancer Biomark, 2012; 11(4):129-37. 10.3233/CBM-2012-0027023144150